[1] Pagano L,Caira M,Candoni A,et al.The epidemiology of fungal infections in patients with hematologic malignancies:the SEIFEM-2004 study[J].Haematologica,2006,91(8):1068-1075.
[2] Singh N,Paterson DL.Aspergillus infections in transplant recipients[J].Clin Microbiol Reviews,2005,18(1):44-69.
[3] Bochennek K,Abolmaali N,Wittekindt B,et al.Diagnostic approaches for immunocompromised paediatric patients with pulmonary infiltrates[J].Clin Microbiol Infect,2006,12(3):199-201.
[4] De Pauw B,Walsh TJ,Donnelly JP,et al.Revised Definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group(EORTC/MSG)consensus group[J].Clin Infect Dis,2008,46(12):1813-1821.
[5] 中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(第三次修订)[J].中华内科杂志,2010,49(5):451-455.
[6] Reichenberger F,Habicht JM,Gratwohl A,et al.Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients[J].Eur Respir J,2002,19(4):743-755.
[7] Pfeiffer CD,Fine JP,Safdar N.Diagnosis of invasive aspergillosis using a galactomannan assay:a meta-analysis[J].Clin Infect Dis,2006,42(10):1417-1427.
[8] Sulahian A,Boutboul F,Ribaud P,et al.Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study[J].Cancer,2001,91(2):311-318.
[9] Mennink-kersten MASH,Ruegebrink D,Klont RR,et al.Release of galactofuranose antigens by different Aspergillus species[C].45th Interscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC).Washington DC,USA;2005:Abstract M-153.
[10] Maertens JA,Klont R,Masson C,et al.Optimization of the Cutoff Value for the Aspergillus Double-Sandwich Enzyme Immunoassay[J].Clin Infect Dis,2007,44(10):1329-1336.
[11] Aquino VR,Goldani LZ,Pasqualotto AC.Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis[J].Mycopathologia,2007,163(4):191-202.
[12] Greene RE,Schlamm HT,Oestmann JW,et al.Imaging findings in acute invasive pulmonary aspergillosis:clinical significance of the halo sign[J].Clin Infect Dis,2007,44(3):373-379.
[13] Caillot D,Latrabe V,Thiebaut A,et al.Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia:an useful tool for diagnosis and assessment of outcome in clinical trials[J].Eur J Radiol,2010,74(3):e172-175.
[14] Maertens J,Buve K,Theunissen K,et al.Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients[J].Cancer,2009,115(2):355-362.
[15] Maertens J,Theunissen K,Verhoef G,et al.Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection:a prospective feasibility study[J].Clin Infect Dis,2005,41(9):1242-1250.
[16] Ji Y,Xu LP,Liu DH,et al.Positive results of serum Galactomannan assays and pulmonary computed tomography predict the higher response rate of empirical antifungal therapy in patints undergoing allogeneic hematopoietic stem cell transplantation[J].Biol Blood Marrow Transplant,2010,[Epub ahead of print].
[17] Sun HY,Singh N.Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients[J].Curr Opin Infect Dis,2009,22(4):394-402.
[18] Miceli MH,Maertens J,Buve K,et al.Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia:proof of principle,description,and clinical and research implications[J].Cancer,2007,110(1):112-120. |
